The future of clinical trials in secondary prevention after acute coronary syndromes

Randomized clinical trials (RCTs) are the gold standard for building evidence. However, the strength of evidence in cardiovascular disease guidelines is not keeping pace with the number of emerging recommendations,1 perhaps reflecting the growing difficulties in developing adequately powered RCTs. In the context of secondary prevention after acute coronary syndromes (ACS), the increase in sample size needed to establish benefit, the rising costs, and the growing complexity of the regulatory environment and study logistics are challenging the development of new therapies. In response to these concerns, the European Society of Cardiology (ESC) convened an ad hoc meeting in May 2009. This paper summarizes the discussions and offers suggestions for improvement (Table 1), which may complement previous proposals.2 [Note: the ideas presented are those of the individual participants (listed in the Appendix) and do not reflect the ideas of the participating bodies]. Strategies to improve research on secondary prevention after acute coronary syndromes Foster better understanding of fundamental pathophysiological mechanisms involved in atherosclerosis progression, thrombus formation and their homeostatic mechanisms Improve the development of animal and non-live human disease models (biosimulation, in silico or virtual models) of vascular disease progression and atherothrombosis Explore new therapeutic targets for atherosclerosis stabilization and/or regression and thrombosis prevention ‘Enrichment’ through recruitment of higher risk patients (elderly, diabetic, chronic kidney disease) Improve external validity: Recruitment of patients from different regions, and reduction of regional variations in processes of care/background therapy Provide log of similar patients contemporaneously treated but not enrolled Identification/measurement of markers or predictors of individual response New creative designs: i.e. ‘intention-to-continue’ (Figure 2) New or improved endpoints: ○ Clinical scores, number of days without symptoms ○ Improve definition, and pre-specified weighing of composite outcomes ○ Establish reliable surrogates Focus on different outcomes: ○ Reducing side-effects ○ Quality of life/return to work ○ Economic evaluation (cost contention, cost-effectiveness) Collection of all data instead of first event Single trials spanning acute coronary syndromes and long-term prevention Strategies to replace old evidence-based treatments instead of incrementally adding new ones Use of registry information for post-marketing surveillance, comparative effectiveness, extending indications, new groups… Foster better understanding of fundamental pathophysiological mechanisms involved in atherosclerosis progression, thrombus formation and their homeostatic mechanisms Improve the development of animal and non-live human disease models (biosimulation, in silico or virtual models) of vascular disease progression and atherothrombosis Explore new therapeutic targets for atherosclerosis stabilization and/or regression and thrombosis prevention ‘Enrichment’ through recruitment of higher risk patients (elderly, diabetic, chronic kidney disease) Improve external validity: Recruitment of patients from different regions, and reduction of regional variations in processes of care/background therapy Provide log of similar patients contemporaneously treated but not enrolled Identification/measurement of markers or predictors of individual response New creative designs: i.e. ‘intention-to-continue’ (Figure 2) New or improved endpoints: ○ Clinical scores, number of days without symptoms ○ Improve definition, and pre-specified weighing of composite outcomes ○ Establish reliable surrogates Focus on different outcomes: ○ Reducing side-effects ○ Quality of life/return to work ○ Economic evaluation (cost contention, cost-effectiveness) Collection of all data instead of first event Single trials spanning acute coronary syndromes and long-term prevention Strategies to replace old evidence-based treatments instead of incrementally adding new ones Use of registry information for post-marketing surveillance, comparative effectiveness, extending indications, new groups… Strategies to improve research on secondary prevention after acute coronary syndromes Foster better understanding of fundamental pathophysiological mechanisms involved in atherosclerosis progression, thrombus formation and their homeostatic mechanisms Improve the development of animal and non-live human disease models (biosimulation, in silico or virtual models) of vascular disease progression and atherothrombosis Explore new therapeutic targets for atherosclerosis stabilization and/or regression and thrombosis prevention ‘Enrichment’ through recruitment of higher risk patients (elderly, diabetic, chronic kidney disease) Improve external validity: Recruitment of patients from different regions, and reduction of regional variations in processes of care/background therapy Provide log of similar patients contemporaneously treated but not enrolled Identification/measurement of markers or predictors of individual response New creative designs: i.e. ‘intention-to-continue’ (Figure 2) New or improved endpoints: ○ Clinical scores, number of days without symptoms ○ Improve definition, and pre-specified weighing of composite outcomes ○ Establish reliable surrogates Focus on different outcomes: ○ Reducing side-effects ○ Quality of life/return to work ○ Economic evaluation (cost contention, cost-effectiveness) Collection of all data instead of first event Single trials spanning acute coronary syndromes and long-term prevention Strategies to replace old evidence-based treatments instead of incrementally adding new ones Use of registry information for post-marketing surveillance, comparative effectiveness, extending indications, new groups… Foster better understanding of fundamental pathophysiological mechanisms involved in atherosclerosis progression, thrombus formation and their homeostatic mechanisms Improve the development of animal and non-live human disease models (biosimulation, in silico or virtual models) of vascular disease progression and atherothrombosis Explore new therapeutic targets for atherosclerosis stabilization and/or regression and thrombosis prevention ‘Enrichment’ through recruitment of higher risk patients (elderly, diabetic, chronic kidney disease) Improve external validity: Recruitment of patients from different regions, and reduction of regional variations in processes of care/background therapy Provide log of similar patients contemporaneously treated but not enrolled Identification/measurement of markers or predictors of individual response New creative designs: i.e. ‘intention-to-continue’ (Figure 2) New or improved endpoints: ○ Clinical scores, number of days without symptoms ○ Improve definition, and pre-specified weighing of composite outcomes ○ Establish reliable surrogates Focus on different outcomes: ○ Reducing side-effects ○ Quality of life/return to work ○ Economic evaluation (cost contention, cost-effectiveness) Collection of all data instead of first event Single trials spanning acute coronary syndromes and long-term prevention Strategies to replace old evidence-based treatments instead of incrementally adding new ones Use of registry information for post-marketing surveillance, comparative effectiveness, extending indications, new groups… In spite of major advances, our understanding of the pathophysiology of coronary atherosclerosis progression and triggers of recurrent thrombotic events after ACS remains limited. To enhance therapeutic development, a clearer picture of coronary atherothrombosis is required. For that, large collaborative consortia between Pharma and acadaemia focused on pathophysiology, genetic epidemiology, new biomarkers, and other intermediate measurements, as well as clinical research on traditional outcomes are needed to better understand the natural history of coronary artery disease. The identification of new pathways and therapeutic targets, as well as the genetic, phenotypic, or behavioural causes underlying the wide individual variations in responses to therapies, particularly antithrombotic treatments should be prioritized. Traditional and new ways of research will be essential to achieve these objectives (Table 1).3 Better ways are also needed to identify patients at high risk for coronary or other vascular recurrences as well as the individual response to treatment perhaps through the emergence of ‘personalized medicine’. Also, more attention should be devoted to the subpopulations whose responses are far from the ‘mean’ responses. The ‘outliers’ are usually diluted in the overall analyses and thus neglected, but may offer keys for interpretation of both atherothrombosis pathophysiology and drug response. Several approaches can be considered, including matching treatments to risk identified by selected phenotypic characteristics (e.g. ACS patients with diabetes, chronic kidney disease, or polyvascular disease), upstream pre-treatment biomarkers (or imaging), on-therapy biomarkers (e.g. response of targets to therapies, pharmacodynamic testing, such as bedside measures of platelet aggregation), or pharmacogenomics, which may help predict response to therapy. Randomized clinical trial populations should reflect the patients who will ultimately receive the study treatment in practice. Therefore, external validity is a major issue for RCTs. First, patients treated in routine clinical practice differ largely from trial participants, who tend to be younger and healthier.4,5 Yet the results of RCTs performed in these highly selected groups are extrapolated to higher risk populations despite the fact that the efficacy and safety of new therapies likely differ across such populations. Second, clinical research was frequently performed away from the most common patient care settings to more academic environments, although this trend may be reversing now.6 Third, large global studies conducted in different countries may not fully reflect regional differences in clinical presentation, patterns of care, and outcomes. Fourth, the scientific and ethical challenges of data from RCTs conducted mainly in developing countries―the so-called globalization of clinical research―are also matters of concern.7 Future RCTs should be ‘enriched’ through increased focus on the ‘underserved’ and higher risk population (Table 1),8 during both the early (Phase 1B and/or adaptive designed trials) and late phases of research. The external validity of new RCTs can also be improved by encouraging recruitment in typical patient clinical-care settings6 in a broad geographic outreach to achieve consistency and geographic validity. Attempts should also be made to reduce regional variations in processes of care and background therapies. Solutions to the problems raised by the conduct of trials in developing countries have been proposed.7 All-cause mortality is the single most important measure of clinical benefit for therapies, and remains the priority for regulators. Given the decline in mortality over recent decades, researchers now need to look beyond this endpoint and focus on non-fatal events. The use of composite endpoints has gained widespread acceptance among clinical trialists but their interpretation is often complex. The combination of ‘hard’ (death, myocardial infarction, stroke) and ‘soft’ (unstable angina, recurrent ischaemia, revascularization) endpoints, of which the latter are much more susceptible to bias, is controversial. If the results of all the components are concordant, interpretation is easier; but this is often not the case. In addition, researchers are attuned to the notion that hierarchy approaches ordinal scoring, but this may not be true for composite endpoints.9 Moreover, it is difficult to balance the trade-off of non-fatal events such as increased bleeding and reduced myocardial infarction risk. Despite these limitations, composite endpoints will continue to have a role. Therefore, the assessment and weighing of non-fatal endpoints have to be refined through the use of standardized definitions, such as those of myocardial infarction,10 stent thrombosis,11 or major bleeding.12 The input of scientific societies will be helpful in solving these problems. Finally, the traditional analysis of time-to-first event in composite endpoints leads to the loss of important information. For better clinical (i.e. competing risks) and economic decisions, it is critical to capture all clinically relevant information and not to dismiss any when there is more than one. The use of clinical scores developed by neurologists (with each outcome weighted individually)—such as the grading of strokes according to disability to communicate the impact on quality of life from the patient's perspective—rather than composite endpoints (with equal weight given to each outcome) has been proposed as alternatives to traditional endpoints. The number of days without symptoms, a variable that combines events and quality of life, has also been proposed.13 The role of novel endpoints, such as reducing side-effects, improving quality of life, cost contention, return to work, and cost-effectiveness, should be discussed. The use of surrogate endpoints (e.g., biomarkers, imaging, functional assessments) that capture patient risk and predict response to a new therapy should in theory make trials easier and less costly. However, they are often unreliable predictors of clinical outcomes and their role is limited as research tools. Much of the evidence for background therapies used after ACS such as aspirin or β-blockers is old, and was obtained in a clinical environment quite different from today's. Some argue that strategies to replace old evidence-based treatments instead of adding new ones on top should be facilitated. This approach faces substantial opposition from ethical committees and regulatory authorities. Scientific societies may assist in revisiting the possible discontinuation of older therapies and the introduction of potentially superior agents. The European Medicines Agency (EMEA) emphasize cardiovascular prevention from a ‘global approach’, and give recommendations based on a ‘continuum of risk’.14 A better knowledge of the similarities or differences in the determinants of early post-ACS events compared with those related to the long-term progression of the disease is needed. The therapeutic implications of the continuum of risk for secondary prevention both early and late after ACS for bridging acute and chronic therapy should be addressed. Also, the potential differences in managing clinical manifestations that may be sustained, such as heart failure, or discrete, such as myocardial infarction deserve attention. Treatments are usually tested in RCTs over relatively short periods (e.g. 12 months), rarely extending beyond 4–5 years. Therefore, the long-term of new therapies are well guidelines often or treatment with therapies, with important economic and safety all long-term therapies be or is there an to and are to be by studies but are of fundamental to patients and The evaluation of possible differences in is both a need and a but the for such analyses is not well trial may for between Single studies spanning the ACS and different post-ACS periods (Figure should be considered, but the to evidence for acute and chronic will have to be analyses and the are strategies of trials may help in the when treatments may be the mechanisms of of novel therapies and their in the different phases of the disease will be in when the therapy is as a prevention of typical trial that patients with ACS as a clinical to those enrolled in chronic between ACS and chronic trials to the benefit of new therapies across the cardiovascular risk The for between ACS and chronic populations is for and should be based on the of of the acute coronary coronary heart disease. and are to the development of RCTs. In they need to be with the mechanisms of of the treatments tested and their clinical in The much cardiovascular prevention research is that by reducing the risk the risk of clinical events is Traditional is based on the of of tested to drug or assessment of outcome after a and of groups according to of the treatment the trials that reduction may be designed is an by a on clinical assessment or evaluation of the risk the trial in and of with by of response such as of in potential outcome of such a trial may be that the risk is when the risk is but there is an when the risk is not there is the in but other are more adaptive are The ‘intention-to-continue’ trial potential outcome of such a a in the event that the risk is as to an in the event that the risk is not are now used but are to i.e. the of less which a to the to which it was This over may in the of and clinically less Some such as Randomized as less and to standard clinical practice compared with by for The recommendations from the RCTs for the evaluation of cardiovascular prevention are given in In the the and that safety for trial participants and improving data the introduction of more and more The of and of the over the A typical is the of which instead of for safety has a in The that and often on clinical research to not clinical trials but The to and improve than increase clinical research should be and clinical trials on secondary prevention after ACS The for should the impact of acute clinical on and long-term outcomes prevention chronic patients with and well risk to interpretation and of study results of patients in each to reliable on the consistency of treatment of care across the of early of drug and impact on of treatment as a potential study to and of treatment is the approach are and are Use of Randomized is drug on top of standard treatment and trial may be of and pre-specified of patients according to relevant clinical of is of All-cause mortality is the endpoint of regulatory for the overall risk benefit to cardiovascular mortality may be overall mortality and mortality For overall mortality and cardiovascular mortality both the and the are relevant for endpoints may be they have similar weight in of clinical benefit and results not by of events and outcomes coronary revascularization) is analysis of a composite endpoint should be based on a analysis of each should be presented cardiovascular disease events need to be for All-cause and/or cardiovascular not used as the endpoint of composite endpoint secondary outcome measure on which a is to be made should be the and secondary efficacy endpoints are as important safety measures overall mortality cardiovascular mortality should a attention on possible on of the cardiovascular risk given to at and failure, pharmacodynamic and should be The for should the impact of acute clinical on and long-term outcomes prevention chronic patients with and well risk to interpretation and of study results of patients in each to reliable on the consistency of treatment of care across the of early of drug and impact on of treatment as a potential study to and of treatment is the approach are and are Use of Randomized is drug on top of standard treatment and trial may be of and pre-specified of patients according to relevant clinical of is of All-cause mortality is the endpoint of regulatory for the overall risk benefit to cardiovascular mortality may be overall mortality and mortality For overall mortality and cardiovascular mortality both the and the are relevant for endpoints may be they have similar weight in of clinical benefit and results not by of events and outcomes coronary revascularization) is analysis of a composite endpoint should be based on a analysis of each should be presented cardiovascular disease events need to be for All-cause and/or cardiovascular not used as the endpoint of composite endpoint secondary outcome measure on which a is to be made should be the and secondary efficacy endpoints are as important safety measures overall mortality cardiovascular mortality should a attention on possible on of the cardiovascular risk given to at and failure, pharmacodynamic and should be European Medicines acute coronary clinical trials on secondary prevention after ACS The for should the impact of acute clinical on and long-term outcomes prevention chronic patients with and well risk to interpretation and of study results of patients in each to reliable on the consistency of treatment of care across the of early of drug and impact on of treatment as a potential study to and of treatment is the approach are and are Use of Randomized is drug on top of standard treatment and trial may be of and pre-specified of patients according to relevant clinical of is of All-cause mortality is the endpoint of regulatory for the overall risk benefit to cardiovascular mortality may be overall mortality and mortality For overall mortality and cardiovascular mortality both the and the are relevant for endpoints may be they have similar weight in of clinical benefit and results not by of events and outcomes coronary revascularization) is analysis of a composite endpoint should be based on a analysis of each should be presented cardiovascular disease events need to be for All-cause and/or cardiovascular not used as the endpoint of composite endpoint secondary outcome measure on which a is to be made should be the and secondary efficacy endpoints are as important safety measures overall mortality cardiovascular mortality should a attention on possible on of the cardiovascular risk given to at and failure, pharmacodynamic and should be The for should the impact of acute clinical on and long-term outcomes prevention chronic patients with and well risk to interpretation and of study results of patients in each to reliable on the consistency of treatment of care across the of early of drug and impact on of treatment as a potential study to and of treatment is the approach are and are Use of Randomized is drug on top of standard treatment and trial may be of and pre-specified of patients according to relevant clinical of is of All-cause mortality is the endpoint of regulatory for the overall risk benefit to cardiovascular mortality may be overall mortality and mortality For overall mortality and cardiovascular mortality both the and the are relevant for endpoints may be they have similar weight in of clinical benefit and results not by of events and outcomes coronary revascularization) is analysis of a composite endpoint should be based on a analysis of each should be presented cardiovascular disease events need to be for All-cause and/or cardiovascular not used as the endpoint of composite endpoint secondary outcome measure on which a is to be made should be the and secondary efficacy endpoints are as important safety measures overall mortality cardiovascular mortality should a attention on possible on of the cardiovascular risk given to at and failure, pharmacodynamic and should be European Medicines acute coronary the in more the to the of new or the increased cost is Economic evaluation the and with the use of therapies. In and are used for and guidelines Economic can also reduce the of clinical trials in different such as to on an study with analysis to the of reducing in a the most focus for studies or to the of information. a to be made as to the benefit is to a often economic are to designed trials and data are in In addition, not all trial data based on events are for economic is in of life and in cost For that, the is an standard for A need is to be to from RCTs. is by differences in risk than in risk. The use of endpoints economic evaluation the of each individual is economic evidence to be standardized to be in different both across and is limited there between in the of economic evaluation (i.e. Economic data have to from relevant particularly when (e.g., coronary for which the patterns of and are outcome including those of and the are essential for economic studies can a broad of large and over periods for a of the cost of a studies are essential for clinical research particularly in practice and quality of care research. and post-marketing are other important for (Table can be performed or in with RCTs including patients who do not the trial but are not are for of the study treatments (e.g. or are by to a registry (e.g. the and of clinical studies therapies and therapeutic practice patterns to guidelines quality of care therapies and therapeutic practice patterns to guidelines quality of care and of clinical studies therapies and therapeutic practice patterns to guidelines quality of care therapies and therapeutic practice patterns to guidelines quality of care The quality of according to designed to a clinical with hoc or or or patient data data registry quality and can impact on data quality and also important which may the of the and the of the obtained (Table are important to complement results but to and scientific societies and regulatory need to guidelines for registry development, the of high quality for effectiveness, and of patient with (i.e. mortality is also important to that the do not with data and To make the evidence more or easier to patient data from both and studies (with data is needed. studies they are not in To will need to be designed in the as including all patients with a given clinical and common and and variable analyses may help reducing but do not In strategies may be to the challenges RCTs in secondary prevention after our knowledge of disease pathophysiology, use of new research for patient new creative or improved traditional new endpoints, improved non-fatal endpoints and and increased use of registry The meeting and this work by the of the European Society of The is a for high between and of has research from and and from and has or other that from and research or from Clinical and and that and/or research has or for to and and in the to from and from and from and The Medicines and research from and and for from The Medicines and is of is of and has been for and from a research from has been a for The Medicines is on the for The Medicines and is a for and from the European Society for the in the of this and was by the European Society of and

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.